TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient diagnosed with moderate to severe Crohn's Disease.~* Failed prior infliximab therapy.~* Patient is judged to be in generally good health as determined by the principal investigator.~Exclusion Criteria:~* Previous treatment with adalimumab.~* Patient considered by the investigator, for any reason, to be an unsuitable candidate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduced PCV Dosing Schedules in South African Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent by the parent/guardian of the child;~2. Born to an HIV-uninfected women, based on testing undertaken as part of standard of care during the last trimester of pregnancy;~3. Had not received any vaccine other than BCG and OPV (routinely given at birth) prior to enrolment;~4. Birth weight \>2499g AND weight of child \>3.5 kg at time of proposed randomization;~5. Aged 42-56 days of age at time of enrolment;~6. Available for the duration of the study;~7. Child is healthy based on medical history and physical examination of the study-staff.~Exclusion Criteria:~1. Any clinically significant major congenital abnormalities;~2. Previous hospitalization for a respiratory illness following discharge from hospital after birth;~3. Receipt of any other investigational drug/vaccine. Co-enrollment into non-investigational studies, including epidemiology studies, is allowed;~4. Any previous PCV vaccination;~5. Known allergy to any of the vaccine components;~6. Febrile illness (axillary temperature ≥37.8°C) at time of enrolment. These participants are eligible if the temperature resolves for at least 48 hours and they remain within the study defined window periods;~7. Planned relocation to outside of the study area during up until age of 2 years;~8. Receipt of blood transfusion or any other blood products (including immunoglobulins) since birth. Receipt of such products during the course of the study, will require withdrawal of the child from the study;~9. History of confirmed pneumococcal disease since birth;~10. Any known or suspected immunodeficiency condition which could affect immune response to vaccination.

- Gender: ALL
- Minimum Age: 5 Weeks
- Maximum Age: 18 Months
- Healthy Volunteers: t

Study Arms:
- Group 1a (1+1, 6 weeks) (Type: EXPERIMENTAL): PCV10 (Synflorix 0.5ml injection) will be administered at 6 weeks and 9 months of age
- Group 1b (1+1, 6 weeks) (Type: EXPERIMENTAL): PCV13 (Prevenar 13, 0.5ml injection) will be administered at 6 weeks and 9 months of age
- Group 2a (1+1, 14 weeks) (Type: EXPERIMENTAL): PCV10 (Synflorix 0.5ml injection) will be administered at 14 weeks and 9 months of age
- Group 2b (1+1, 14 weeks) (Type: EXPERIMENTAL): PCV13 (Prevenar 13, 0.5ml injection) will be administered at 14 weeks and 9 months of age
- Group 3a (2+1) (Type: ACTIVE_COMPARATOR): PCV10 (Synflorix 0.5ml injection) will be administered at 6 weeks, 14 weeks and 9 months of age, as per EPI schedule in South Africa
- Group 3b (2+1) (Type: ACTIVE_COMPARATOR): PCV13 (Prevenar 13, 0.5ml injection) will be administered at 6 weeks, 14 weeks and 9 months of age, as per EPI schedule in South Africa

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Decapeptyl SR With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* aged between 18 and 45 years inclusive~* have a clinical diagnosis of chronic cyclical pelvic pain of at least 6 months duration (with or without evidence of endometriosis)~* have had investigations for possible endometriosis within three years prior to screening visit~* had regular menstrual cycles (24-42 days) for 3 months prior to screening~* treatment with LHRHa is indicated~* must be able to understand and be willing to comply with the requirements of the protocol~Exclusion Criteria:~* treated with any LHRHa within 6 months prior to screening~* treated with danazol, gestrinone or cyproterone acetate within 6 months prior to screening~* used cyclical progesterones or combined oral contraceptives within one full menstrual cycle prior to screening~* treated with any other medication other than analgesics within 3 months prior to screening~* continuous or acyclical pelvic pain~* known metabolic bone disease~* abnormal full blood count or liver or renal function at screening or within 6 months~* unexplained vaginal bleeding~* bone mineral density age adjusted T Score of -2 or below at screening visit.~* any other medical condition or abnormality that would impact on the safety or efficacy of the study treatment~* receiving treatment with coumarin or indanedione derivatives~* known contraindication or allergy or hypersensitivity to test compounds~* pregnancy or lactation~* planning a pregnancy within 31 months of screening~* of child bearing potential and unwilling to use adequate barrier contraception for the duration of the study~* received any investigational drug therapy within 30 days prior to the study~* has previously entered the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of MDS~* Adequate liver and kidney function~* Ineligible for, or refusing, allogeneic bone marrow transplant~* At least 18 years of age~* Discontinuation of growth factors (e.g., G- CSF) at least 2 weeks prior to study entry~Exclusion Criteria:~* Failure to recover from any prior surgery, or any major surgery within 4 weeks of study entry~* Pregnant or lactating women~* History of allergy to eggs~* Other investigational drugs within 14 days of study entry~* Chemotherapy, radiotherapy or immunotherapy within 14 days of study entry~* Concomitant steroids or hormones for the treatment of neoplasms

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18 years.~* Estimated glomerular filtration rate (eGFR) ≤ 45 ml/min/1.73m2 but ≥20 mL/min/1.73m2.~* Poorly controlled blood pressure by 24-hour ambulatory blood pressure (BP) monitoring.~* Treated hypertension: use of at least one antihypertensive drug. One of the drugs should be either an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB). If these are contraindicated then use of a beta-blocker is required.~Exclusion Criteria:~* Use of thiazide or thiazide-like drugs in the previous 3 months.~* Use of furosemide in a dose \>200 mg/d.~* Ambulatory BP of either ≥160 systolic or ≥100 mmHg by 24-hour ambulatory BP monitoring.~* Expected to receive renal replacement therapy within the next 3 months.~* Vascular event such as myocardial infarction, heart failure hospitalization, or stroke within 3 months prior to randomization.~* Pregnant or breastfeeding women or women who are planning to become pregnant or those not using a reliable form of contraception (oral contraceptives. condoms and diaphragms will be considered reliable).~* Known hypersensitivity to thiazide or sulfa drugs.~* Organ transplant recipient or therapy with immunosuppressive agents. Nasal or inhaled corticosteroids will be permitted.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Psoriasis for 6 mo.~* BSA 10%, PASI 12 or above, PGA 3 or above~Exclusion Criteria:~* Previous exposure to either etanercept or ABT-874

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: ACTIVE_COMPARATOR): None
- C (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness Study of a Candidate Vaginal Microbicide for Prevention of HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-40 years (inclusive)~* Able and willing to provide written informed consent to be screened for, and to enrol in, the study.~* Able and willing to provide adequate locator information for study retention purposes.~* Sexually active, defined as having had vaginal intercourse at least twice in the past 30 days prior to screening.~* HIV negative on testing performed by study staff within 30 days of enrolment.~* Have a negative pregnancy test which was performed by study staff within 21 days of enrolment~* Agree to use a non-barrier form of contraceptive~* Agree to adhere to study visits and procedures~Exclusion Criteria:~* History of adverse reaction to latex.~* Plans any of the following during the next 16 to 30 months (depending the anticipated date of study completion):~  * To travel away from the study site for more than 30 consecutive days.~ * To relocate away from the study site.~ * To become pregnant~ * To enrol in any other study of an investigational product or behaviour modification related to HIV prevention.~* Has a creatinine clearance \<50ml/min, as estimated using the method of Cockcroft and Gault(33).~* Has active Hepatitis B infection (since January 2009)~* Has a clinically apparent pelvic examination finding (observed by study staff) involving deep epithelial disruption. Otherwise eligible participants with pelvic examination findings involving deep epithelial disruption may proceed with enrolment after the findings have resolved and the inclusion/exclusion are met.~* Has in the past year participated in any research related to any vaginally applied product/s.~* Has current STI symptoms and/or other reproductive tract infection requiring treatment, as assessed by study staff. Otherwise eligible participants diagnosed during screening with infection(s) requiring treatment may be enrolled provided that treatment has commenced.~* Has any other condition that, based on the opinion of the Investigator or designee, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Tenofovir gel (a reverse transcriptase inhibitor)
- 2 (Type: PLACEBO_COMPARATOR): Universal HEC placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Smoking Termination Enhancement Project (STEP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged between 18 and 65 years old~2. Capable of providing informed consent, attend all study visits and comply with the protocol~3. Daily smoker for at least one year and currently smoke an average of at least 10 cigarettes per day~4. Report a motivation to quit smoking in the next month of at least 5 on a 10-point scale~5. Score of 20 or greater on 16-item Anxiety Sensitivity Index~6. Physically inactive as defined as participating in moderate-intensity exercise less than 2 days/week (duration must be 30 minutes or less each time)~Exclusion Criteria:~1. Use of other tobacco products~2. General medical condition(s) that contraindicate exercise~3. Resting blood pressure of ≥ 160 systolic and/or 100 diastolic who are not receiving treatment for high blood pressure~4. Blood lipid levels ≥ 240 mg/dl with LDL-C ≥ 160 mg/dl or triglyceride levels ≥ 300 mg/dl (individuals receiving medical treatment for lipid abnormalities with lipid levels above the cut-offs will be eligible with physician written approval)~5. Body mass index ≥40~6. Currently suicidal or high suicide risk~7. Current or past psychotic disorders of any type, or comorbid psychiatric conditions that are relative or absolute contraindications to the use of any treatment option in the study protocol~8. Currently pregnant, planning on becoming pregnant in the next year, or current breastfeeding~9. Alcohol or drug dependence; abuse of depressants, dissociative anesthetics, hallucinogens, opioids, or cocaine within the last 6 months~10. Psychotherapy initiated within the past three months, or ongoing psychotherapy of any duration directed specifically toward the treatment of anxiety or mood disorder other than general supportive therapy~11. Current use of any psychotherapy or pharmacotherapy for smoking cessation not provided by the researchers, including Chantix, Zyban, Welbutrin and Nortriptyline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Standard Care plus Wellness Program (Type: ACTIVE_COMPARATOR): None
- Standard Care plus Exercise Program (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females ≥18 years of age.~2. Requirement for dental surgery for extraction of ≥2 x third molars, at least 1 of which involves partial or complete mandibular bony impaction.~3. Pain Intensity (PI) using a Numeric Pain Rating Scale (NPRS) ≥5 during the 5 hours following the end of surgery.~4. Rating of moderate or severe pain on a 4-point categorical pain rating scale (i.e., none, mild, moderate, severe) during the 5 hours following the end of surgery.~Exclusion Criteria:~1. Previously dosed with MR-107A-01.~2. Subject with known hypersensitivity to nonsteroidal antiinflammatory drugs (NSAIDs).~3. Active GI bleeding or a history of peptic ulcer disease, active inflammatory bowel disease, e.g., Crohn's Disease or ulcerative colitis, bleeding disorders that may affect coagulation.~4. Use of any investigational drug within 28 days, or 5 half-lives, prior to screening whichever is longer.~5. Use of medications with the potential to interact with MR-107A-01.~6. Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MR-107A-01 15 mg once in a 24-hour period (Type: EXPERIMENTAL): Oral tablet one day of dosing
- MR-107A-01 10 mg once in a 24-hour period (Type: EXPERIMENTAL): Oral tablet one day of dosing
- MR-107A-01 15 mg twice in a 24-hour period (Type: EXPERIMENTAL): Oral tablet one day of dosing
- MR-107A-01 10 mg twice in a 24-hour period (Type: EXPERIMENTAL): Oral tablet one day of dosing
- Placebo twice in a 24-hour period (Type: PLACEBO_COMPARATOR): Placebo tablet one day of dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Misoprostol Ripening Efficacy With Dilapan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women undergoing labor induction with a gestation of ≥37 weeks (based on a sure last menstrual period and an ultrasound done before 22 0/7 weeks)~2. Live fetus with in cephalic presentation~3. Singleton pregnancy~4. Able to provide informed consent for participation in the study~Exclusion Criteria:~1. Contraindication for vaginal delivery~2. Age less than 18 years~3. Prior uterine scar from a cesarean section or myomectomy~4. Patients who have HELLP syndrome or eclampsia~5. Active genital herpes at the time of labor induction~6. Complex medical problems that may require assistance with second stage of labor~7. Bishop score ≥ 6~8. Major fetal congenital anomalies (as assessed by investigator)~9. Premature rupture of membranes

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Dilapan group (Type: EXPERIMENTAL): Patients who are randomized to receive Dilapan, will have 3-5 rods of Dilapan-S® inserted in their cervix by the supervising provider, under aseptic precautions with a speculum exam, either digitally or using a sponge forceps, as per manufacturer's recommendations. The Bishop score at the time of eligibility assessment and number of rods inserted will be recorded. Dilapan will be left in cervix for 12 hours. Patients will be allowed to ambulate, shower and have light meals as long as they meet the criteria based on institutional guidelines for intermittent fetal heart monitoring. Nothing per vagina including douching and no bathing is allowed.
- Misoprostol group (Type: EXPERIMENTAL): Patients who are randomized to Misoprostol group, after the baseline assessment and a reassuring cardiotocograms (CTG) monitoring for 20 minutes to a maximum of 6 doses. All subjects will have continuous fetal monitoring. A dose will be held if patient is noted to have uterine tachysystole, hyperstimulation, fetal heart tracing abnormalities or 3 or more painful uterine contractions over a period of 10 minutes (indicating onset of labor). Administration of Misoprostol will be done by the nurse assigned to the patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ear Drops for Children With Otitis Media

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presenting to participating clinic with otitis media~* Diagnosed with acute otitis media~* Parents rate symptoms as a moderate problem or more~Exclusion Criteria:~* Diagnosis of otitis media within preceding 30 days~* Receipt of antibiotics within 2 days~* Perforated ear drum or bullous lesion~* Receipt of homeopathic treatment within 30 days

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): homeopathic ear drops in addition to standard care for otitis media
- 2 (Type: NO_INTERVENTION): No ear drops, standard care for otitis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete